The purpose of the study was to assess the impact of number of salvage regimens needed to demonstrate chemotherapy sensitivity on relapse rates, survival, and toxicity following high-dose therapy and autologous bone marrow transplantation (ABMT) in relapsed or refractory non-Hodgkin's lymphoma. We retrospectively reviewed 136 patients with intermediate-grade lymphoma who underwent ABMT. All patients were treated with salvage therapy to maximum tumor reduction. Three quarters (102/136) of the patients received one salvage regimen, while 31 (23%) patients received two or more regimens. When compared to patients requiring у two regimens, patients requiring only one salvage regimen to demonstrate chemosensitivity were more likely to have a longer previous CR from initial therapy (CR у12 months in 47% vs 26%; P = 0.04) and to have attained CR with salvage (54% vs 16%; P = 0.001). Both median relapse-free survival (RFS) and overall survival (OS) have not yet been reached in patients receiving one salvage regimen (median follow-up 50.6 months). This is superior to the median RFS of 9.1 months (P = 0.004) and OS of 11.1 months in patients requiring уtwo regimens to demonstrate chemosensitivity (P = 0.002). Time to engraftment, toxic deaths and incidence of myelodysplasia were similar in the groups. The survival rate observed in patients requiring уtwo salvage regimens, although inferior to that of patients receiving a single salvage regimen, are still generally superior to results in the literature for patients treated with chemotherapy alone without ABMT. We conclude that high-dose therapy with ABMT is appropriate for lymphoma patients even when disease reduction requires repeated numbers of salvage regimens. Keywords: lymphoma; transplant; salvage; chemotherapy; chemosensitivity Sensitivity to salvage chemotherapy is one of the strongest predictors of outcome after high-dose therapy with autologous bone marrow or peripheral blood stem cell transplantation (ABMT) in relapsed or refractory non-Hodgkin's lymphoma.
Sensitivity to salvage chemotherapy is one of the strongest predictors of outcome after high-dose therapy with autologous bone marrow or peripheral blood stem cell transplantation (ABMT) in relapsed or refractory non-Hodgkin's lymphoma. [1] [2] [3] [4] [5] [6] Numerous salvage chemotherapy regimens have been used to reduce disease bulk and test chemosensitivity, but no single regimen appears superior. In general, initial response rates of 30-50% with salvage therapy are attainable. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Those who do not respond or have disease progression with first-line salvage tend to fare poorly with high-dose therapy and may proceed to second-or even third-line salvage treatment with the hope of qualifying for high-dose therapy and ABMT. This approach may seem reasonable, particularly in young patients with good performance status, but has not been validated in the literature. Requiring more than one salvage regimen to attain an adequate response may reflect greater intrinsic drug resistance or may identify patients with a less favorable natural history predicting for transplant failure, regardless of the disease status ultimately achieved. Hence, the use of multiple salvage regimens pre-ABMT raises concerns of greater risk-to-benefit ratio and poor utilization of limited resources. Even in the event of successful remission with transplant, these patients may experience increased transplant-related toxicity, prolonged recovery post-transplant and decreased quality of life.
At our center, patients with relapsed or refractory intermediate-grade NHL are eligible for autologous transplantation if they demonstrate chemosensitivity after salvage therapy. Patients with no response to initial salvage who continue to have a good performance status have been offered second-and occasionally third-line treatment. In the present study, we performed an analysis of patients with relapsed or refractory intermediate-grade NHL who underwent autologous transplantation to assess the impact of the number of salvage regimens needed to demonstrate chemosensitivity. Three outcomes were assessed: relapse, overall survival and toxicity.
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Patients and methods
Patients
From August 1987 to October 1997, 136 patients with relapsed or primary refractory intermediate-grade NHL underwent autologous bone marrow or stem cell transplantation at the University Health Network in Toronto. Intermediate-grade histology included follicular large cell, diffuse small cleaved cell, diffuse mixed cell, diffuse large cell, and immunoblastic NHL as classified by the Working Formulation. 17 T cell rich B cell and CD30-positive anaplastic large cell lymphomas were also included in the analysis. Patients with intermediate-grade histology that had transformed from a previous low-grade lymphoma were excluded from this analysis. All patients had previously received an anthracycline-containing induction regimen with either primary resistance or subsequent relapse. Patients with multiple relapses treated with conventional chemotherapy were included.
Staging at relapse included chest radiography, computed tomography (CT) of the chest, abdomen and pelvis, unilateral bone marrow (BM) aspirate and biopsy and, in most patients, whole body gallium scanning. Lumbar puncture for cerebrospinal fluid (CSF) assessment and additional imaging were performed if clinically indicated. To be eligible for transplantation, chemosensitivity to a salvage regimen was required as described previously. 6 Patients with a partial response (PR) to salvage therapy proceeded to ABMT if residual disease bulk measured р5 cm in diameter at all sites. Patients with central nervous system (CNS) or BM involvement were included providing all signs of disease, including CSF abnormalities, had cleared and the BM biopsy showed <15% residual lymphoma after salvage therapy. Other eligibility criteria for transplantation were age р65 years, normal cardiac ejection fraction by MUGA scanning, and adequate renal, hepatic and pulmonary function, with performance status р2 (ECOG). 18 
Treatment
Salvage regimens were initiated either by the patient's primary oncologist or at the recommendations of the transplant team after evaluation at our center. A standard two cycles of the initial regimen were generally administered before restaging to assess response. Patients responding after two cycles but not attaining minimum criteria for transplantation generally received an additional cycle. Patients who progressed or had no response to initial salvage therapy (2-3 cycles) were offered second-line and occasionally third-line therapy to maximum response, provided they had adequate performance status and bone marrow reserve. The need for pre-or post-transplant irradiation was determined based on disease bulk prior to salvage chemotherapy and whether normal tissue tolerance would be exceeded. Eligible patients underwent BM harvest or, more recently, peripheral blood stem cell collection using cyclophosphamide and G-CSF 19 for stem cell mobilization. Response after chemotherapy used for mobilization was not considered separately in determining whether a patient was chemosensitive.
The high-dose therapy regimen used for all patients included etoposide 60 mg/kg in either a 5-or 32-h infusion on day Ϫ4, melphalan 180 mg/m 2 on day Ϫ3 followed by peripheral blood stem cell or marrow infusion on day 0. Total body irradiation (TBI) 2 Gy twice daily for six fractions on day Ϫ2, Ϫ1 and 0 was included in the intensive therapy regimen for patients with skin involvement, evidence of low-grade component on biopsy, and T cell immunophenotype, in which case the dose of melphalan was reduced to 160 mg/m 2 .
Statistical analysis
Data on ABMT patients at The Toronto Hospital were collected prospectively from the time of referral; however, complete data on LDH at relapse was not always available during the time course for this analysis. For this reason we were unable to determine the age-adjusted International Prognostic Index (IPI) 20 on the complete cohort of patients. Statistical analyses were performed with the SPSS Statistical Program. Survival analyses were performed with the Kaplan-Meier method 21 with endpoints of relapse or death compared using the log-rank test 22 between patient groups defined by number of salvage regimens received. The chisquare method 23 was used to compare categorical variables between patients. Time to platelet and neutrophil engraftment was analyzed between regimen groups using the Kaplan-Meier method.
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Results
Patient characteristics
Characteristics of the 136 patients are outlined in Table 1 . The median age at time of transplantation was 47 years Table 2 ). More patients receiving only one salvage regimen attained a CR at time of transplant (P = 0.001) and had initial CR duration у12 months (P = 0.04) compared to those receiving two or more regimens. No other differences in patient and disease characteristics were noted.
Salvage therapy prior to transplant
The treatment received prior to proceeding to high-dose therapy and ABMT is summarized in Table 3 . Three quarters (102/136) of the patients received one salvage regimen, Bone Marrow Transplantation 26 (19%) patients required two regimens and five (4%) received three regimens before proceeding to ABMT. Three patients did not receive any salvage therapy prior to transplant due to minimal disease at relapse. The most common first-line regimen used was DHAP (dexamethasone, highdose Ara-C, cisplatin) 15 in 57 (41%) patients followed by miniBEAM (BCNU, etoposide, Ara-C, melphalan) 10 in 46 (33%) patients. There was no difference in the proportion of patients in the two groups receiving one or other of these two regimens: of those who needed only one regimen, 51% received DHAP and 37% miniBEAM; whereas among those who utimately needed two or more regimens, 39% received DHAP and 32% miniBEAM for their first salvage treatment (Chi square P = 0.30 for DHAP, and P = 0.66 for mini-BEAM). Overall, 77% and 71% of the patients requiring two or more salvage regimens before transplant received DHAP and mini-BEAM, respectively. Other regimens used (most often as second-or third-line salvage) included ESHAP, 24 CHOP, 25 EPOCH, 16 paclitaxel, 26, 27 DICE, 11 and MACOP-B. 28 The mean total number of cycles (including all salvage regimens) was three (range, 0-11). The median number of cycles for patients receiving a single regimen was two (range, 1-7) and four (range, 2-8) for those requiring two or more regimens. Radiation therapy was given to 58 patients (43%) to improve local control at sites of previous bulky disease and was generally administered following ABMT. Four patients were given radiation therapy to attain adequate tumor debulking prior to transplant (all had failed first-line salvage chemotherapy). There were no differences in radiation use between groups receiving one, or more than one salvage chemotherapy regimen.
Relapse and survival outcomes
The 5-year relapse-free survival (RFS) for the entire cohort of 136 patients is 48% (standard error (s.e.) 5%) and 5-year overall survival (OS) was 49% (s.e. 5%) (Figures 1  and 2 ). Treatment outcome according to the number of regimens of salvage therapy received (1 vs у2 regimens) is shown in Table 4 . The three patients with untested relapse (no salvage therapy given) were not included in the com- Five patients receiving TBI also received involved field consolidative radiation. parative analyses. Median RFS for the one regimen group has not been reached, at a median follow-up of 51 months, compared to 9 months for the patients receiving у2 regimens (P = 0.004, Figure 3 ). Five-year RFS for patients receiving one regimen was 56% (s.e. 5%) and for those receiving уtwo regimens was 23% (s.e. 9%). Median OS in the single salvage regimen group again has not yet been reached and was superior to the median OS of patients receiving у2 regimens (11 months, P = 0.002) (Figure 4) . Overall survival at 5 years for patients requiring only one regimen was 57% (s.e. 5%), and for two or more regimens was 25% (s.e. 9%). The outcome for the 13 patients whose disease progressed during their first salvage attempt, but who had at least a partial response to a second regimen, is similar to the 18 patients who received two salvage regimens because they had a decrease in tumor mass that did not satisfy the previously outlined criteria for partial response, or had residual bulk Ͼ5 cm with the first regimen (P = 0.51, log rank test).
Among the patients treated with one regimen prior to ABMT there were nine toxic deaths (9%) whereas in the у2 regimen group, there were four toxic deaths (13%, P = 0.56). The majority of deaths in both groups were attributable to respiratory/infectious complications (onset between 8-104 days post transplant).
When stratified by radiation alone, the patient group receiving some form of radiation as part of planned cytoreduction had a better survival (median not yet reached at follow-up) than those who did not (median survival 44.3 months, P = 0.08 ( Figure 5) ). There was no such trend with RFS. When analyzed by the Kaplan-Meier method according to whether one vs two or more salvage regimens were required, radiation use did not lead to significant differences in relapse or survival outcomes between the groups. Of the four patients who were only able to proceed to ABMT following radiotherapy debulking, three remain alive at time of analysis without relapse (23, 44 and 48 months post transplant) and the fourth died of treatment-related toxicity.
Times to achieve an unsupported platelet count у20 ϫ 10 9 /l and absolute neutrophil count (ANC) у0.5 ϫ 10 9 /l for 2 consecutive days were similar in both groups (Table 4) . Six patients in the entire cohort, five having received one salvage regimen and one receiving у2 regimens, have developed myelodysplasia at a median interval of 45.7 months from transplant (range 6.1 to 72 months). At the time of analysis, all patients with myelodysplasia are in continuous remission from their lymphoma.
Discussion
The Parma study, a large multi-center randomized trial, compared high-dose chemotherapy and ABMT to conventional-dose salvage therapy in relapsed aggressive nonHodgkin's lymphoma (NHL). 29 Survival outcomes significantly favored ABMT over the conventional therapy arm, thus establishing the former as the standard of care for chemosensitive, relapsed NHL. Chemosensitivity -a requirement for randomization in that study -was tested with a standardized two cycles of DHAP salvage therapy. As a result, approximately half of the patients were deemed chemosensitive and could be randomized to transplant. In attempts to expand this population of patients eligible for ABMT, one treatment option is to use repeated cycles and/or multiple regimens of salvage therapy in any given patient. Response rates are reported to decline from 30-50% with first-line salvage therapy to 15-16% (CR only 3%) with second-line salvage. 10 Nonetheless, patients who ultimately attain marginal responses after multiple salvage regimens may proceed to transplantation with similar expectations of success to those who demonstrated chemosensitivity with their initial salvage regimen.
At our center, one-quarter of our 136 patients with aggressive histology NHL received two or more salvage regimens to attain adequate tumor reduction prior to autologous stem cell transplantation. We have shown that these patients have significantly lower overall and relapse-free survivals from time of transplant compared to patients requiring only one salvage regimen. As toxic death rates Bone Marrow Transplantation did not differ between our groups, it is unlikely that the difference in overall survival reflects cumulative toxicity predisposing to greater transplant-related mortality.
The outcome of patients with aggressive NHL in relapse who are refractory to chemotherapy is poor and there are few reports in the literature describing the results of attempts to salvage this group of patients. Even those who have a partial response to initial salvage therapy without the addition of ABMT do poorly. In a cohort of 156 patients treated with ESHAP reported by Rodriguez-Monge and Cabanillas, 30 only two of 29 who achieved a PR with ESHAP remain alive more than 5 years after treatment, and both were salvaged with other therapies. Blay et al 31 reported the outcome of patients in the Parma trial who failed to respond to two cycles of induction therapy with DHAP and were therefore not randomized. For 88 patients for whom information on subsequent treatment was available, the overall survival from date of relapse was significantly superior for the 18 patients who later received highdose chemotherapy with stem cell support, compared to those who did not. The IPI at relapse was available in 82 patients: those with an IPI of 0 or 1 who underwent ABMT had significantly superior survivals compared to those who did not undergo ABMT. In contrast, survival of those with an IPI of 2 or 3 who received ABMT was comparable to that of patients treated with conventional-dose chemotherapy. These data suggest that the IPI assigned at time of relapse may be useful in determining whether patients who have not responded to initial salvage therapy should continue to pursue potentially curative treatment with high-dose chemotherapy and ABMT, or should more appropriately be treated with more conservative palliative approaches.
We did not have sufficiently detailed data on patients at the time of relapse to determine the age-adjusted IPI for all patients in this series. Of the nine patients currently alive who had received two (8) or three (1) salvage regimens, three were in CR and six were in PR prior to transplant. For the six patients who had relapsed, the duration of initial CR was <12 months in five patients; the other three patients were treated because they were refractory to initial chemotherapy at diagnosis. These characteristics, although limited by the small number of patients, do not suggest that the long-term survivors who required two salvage regimens to show chemotherapy sensitivity, had disease characteristics that were more favorable than the entire cohort receiving ABMT at our center.
It may be argued that more limited chemotherapy exposure is advantageous, possibly by minimizing the development of acquired drug resistance. Alternatively, the need for multiple salvage regimens to attain a response may identify biologically aggressive disease with an intrinsically lower likelihood of durable remission after ABMT. We found no difference between those patients receiving one vs two or more regimens when assessed for markers of aggressive disease such as advanced stage and extranodal disease at diagnosis. 20 In our study, the presence of advanced stage at time of relapse was similar in our two comparison groups, but significantly more patients requiring multiple salvage regimens had extranodal disease at relapse. Bulky disease at the time of transplant, cited as a Bone Marrow Transplantation predictor of transplant failure, 4, 32, 33 could not be analyzed in our patients due to our policy of excluding such patients from transplant. We did note, however, that patients requiring more salvage to achieve at least a partial response were likely to have a shorter CR (р12 months) from initial therapy. In a review of the patients in the PARMA trial, longer time to relapse after initial induction chemotherapy correlated highly with response to DHAP salvage therapy and was predictive of survival regardless of treatment regimen after DHAP (ABMT or continuing salvage therapy). 34 Disease status at the time of transplant predicts strongly for survival after high-dose therapy.
1,4-6 Though often equated with chemosensitivity, disease status is a more subtle prognostic factor. We have previously reported a significant difference in long-term progression-free survival between patients attaining a CR (60%) vs a PR (25%) with salvage therapy prior to ABMT. 6 In the present analysis, over half of the patients who received a single salvage regimen were in CR before transplant, in contrast to only 16% of those who received у2 regimens (P = 0.01). Hence, poor transplant outcomes in the latter group may be related to residual disease bulk. If one assumes that disease bulk denotes tumor that is inaccessible to ablation with highdose therapy, debulking by any means such as with radiotherapy would be expected to yield superior transplant outcomes. Several retrospective studies have suggested that the use of involved field radiation in the pre-or post-transplant period to sites of residual disease improves event-free survival. 4, 35, 36 This effect is accentuated in patients with bulky tumor at time of transplant. 4 In our entire cohort of patients, we noted a trend towards prolonged survival with radiotherapy use, but the addition of radiation to multiple salvage regimens did not seem to affect outcomes. These observations should be interpreted cautiously because of the small number of patients analyzed and the non-random use of radiation. Interestingly, three of our four patients debulked with radiation (due to chemoresistance) have remained free of relapse at 2 to 4 years of follow-up posttransplant. This may suggest that chemosensitivity portends favorable results simply by reducing tumor bulk.
In our patient group receiving у2 salvage regimens, we observed a 5-year RFS of 23% and OS rate of 25% from the time of transplant. Despite inferiority to the outcome of the single salvage regimen group, these results appear generally superior to those of patients treated with conventional chemotherapy alone in the literature. 9, 11, 12, 15, 29, 30 Importantly, we did not find that using multiple salvage regimens led to excessive toxicity such as delayed engraftment times, toxic deaths or late effects, such as myelodysplasia. Our data suggest that high-dose chemotherapy with stem cell support may still be considered an option for patients who do not respond to their initial chemotherapy salvage regimen, provided they show chemotherapy sensitivity to subsequent treatment. This approach is most likely to be successful in producing durable remissions in patients with a low IPI score at relapse.
